AIDS - Related Lymphoma - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 84

AIDS - Related Lymphoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'AIDS - Related Lymphoma - Pipeline Review, H2 2012', provides an overview of the AIDS - Related Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for AIDS - Related Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for AIDS - Related Lymphoma. 'AIDS - Related Lymphoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for AIDS - Related Lymphoma.
- A review of the AIDS - Related Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the AIDS - Related Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for AIDS - Related Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding AIDS - Related Lymphoma pipeline depth and focus of AIDS - Related Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

AIDS - Related Lymphoma Therapeutic Products under Development, Key Players in AIDS - Related Lymphoma Therapeutics, AIDS - Related Lymphoma Pipeline Overview, AIDS - Related Lymphoma Pipeline, AIDS - Related Lymphoma Pipeline Assessment

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
AIDS - Related Lymphoma Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for AIDS - Related Lymphoma 8
AIDS - Related Lymphoma Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
AIDS - Related Lymphoma Therapeutics – Products under Investigation by Universities/Institutes 14
AIDS - Related Lymphoma – Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
Doxil + Methotrexate + Prednisone + Vincristine Sulfate + Sargramostim - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
cART + R-EPOCH - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 25
CHOP-BLEO + Radiation Therapy - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 27
FLEP + Radiation Therapy - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ASHAP + IMVP16 + Radiation Therapy - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 32
Methotrexate + Zidovudine + Radiation Therapy - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Filgrastim + Cyclophosphamide + Cytarabine + Methotrexate + Pegylated Liposomal Doxorubicin Hydrochloride + Prednisone + Vincristine Sulfate + Radiation Therapy - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 36
BCNU + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Cell Transplantation - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
EPOCH Regimen + Methotrexate + Prednisone + Cytarabine + Filgrastim - Drug Profile 40
Product Description 40
Mechanism of Action 41
R&D Progress 42
Filgrastim + Pegfilgrastim + Rituximab + Cyclophosphamide + Cytarabine + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Leucovorin Calcium + Liposomal Cytarabine + Methotrexate + Therapeutic Hydrocortisone + Vincristine Sulfate - Drug Profile 44
Product Description 44
Mechanism of Action 45
R&D Progress 46
R-EPOCH + cART - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 49
Sunitinib - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
G-CSF + Cyclophosphamide + Etoposide + Lomustine + Procarbazine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
G-CSF + Cyclophosphamide + Etoposide + Lomustine + Procarbazine Hydrochloride + Radiation Therapy - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 54
ProMACE-CytaBOM + TMP-SMX + G-CSF + Radiation therapy - Drug Profile 55
Product Description 55
Mechanism of Action 56
R&D Progress 57
Bleomycin - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Filgrastim + Rituximab + Sargramostim + Cyclophosphamide + Doxil + Prednisone + Vincristine Sulfate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 61
Rituximab + EPOCH - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 63
Rituximab + EPOCH + Vorinostat - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 65
R-CHOP - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
R-CHOP + Vorinostat - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 69
Etoposide + Methylprednisolone Sodium Succinate + Carboplatin + AraC + Rituximab + MCNU + L-PAM + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 71
CHOP + Rituximab + Peripheral Blood Stem Cell Transplantation - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 73
HAART + Methotrexate + Rituximab + Leucovorin - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 75
Velcade + Carboplatin + Dexamethasone + Etoposide + Ifosfamide - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 77
Fludarabine + Busulfan + Melphalan + Cyclophosphamide + Total Body Irradiation + Allogeneic Hematopoietic Cell Transplantation - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 79
AIDS - Related Lymphoma Therapeutics – Drug Profile Updates 80
AIDS - Related Lymphoma Therapeutics – Discontinued Products 81
AIDS - Related Lymphoma Therapeutics - Dormant Products 82
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84

List of Tables
Number of Products Under Development for AIDS - Related Lymphoma, H2 2012 8
Products under Development for AIDS - Related Lymphoma – Comparative Analysis, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 15
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
AIDS - Related Lymphoma Therapeutics – Drug Profile Updates 80
AIDS - Related Lymphoma Therapeutics – Discontinued Products 81
AIDS - Related Lymphoma Therapeutics – Dormant Products 82

List of Figures
Number of Products under Development for AIDS - Related Lymphoma, H2 2012 8
Products under Development for AIDS - Related Lymphoma – Comparative Analysis, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21

Customers who bought this item also bought

• Chronic Lymphoblastic Lymphoma - Pipeline Review, H2 2012
• Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012
• Lymphoma - Pipeline Review, H2 2012
• Non-Hodgkin Lymphoma - Pipeline Review, H2 2012
• Other Hematological Disorders - Pipeline Review, H2 2012
• Neurofibromatoses - Pipeline Review, H2 2012
• Retinopathy - Pipeline Review, H2 2012
• Nausea - Pipeline Review, H2 2012
• Fatty Liver Disease - Pipeline Review, H2 2012
• Thrombocytopenia - Pipeline Review, H2 2012